CN100490807C - Cephalofruxin ester liposome, its preparation and medicinal composition containing it - Google Patents
Cephalofruxin ester liposome, its preparation and medicinal composition containing it Download PDFInfo
- Publication number
- CN100490807C CN100490807C CNB2006101497036A CN200610149703A CN100490807C CN 100490807 C CN100490807 C CN 100490807C CN B2006101497036 A CNB2006101497036 A CN B2006101497036A CN 200610149703 A CN200610149703 A CN 200610149703A CN 100490807 C CN100490807 C CN 100490807C
- Authority
- CN
- China
- Prior art keywords
- cephalofruxin
- cefuroxime axetil
- liposome
- ester liposome
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Abstract
A liposome of cefuroxime axetil used to prepare the tablet with high target performance to the gastrointestinal mucosa cells is prepared from cefuroxime axetil, soybean lecithin and chlosterol in weight ration of 1:2:2. Its preparing process is also disclosed.
Description
Technical field
The present invention relates to a kind of Cephalofruxin ester liposome, its preparation method and contain its pharmaceutical composition, belong to medical technical field.
Background technology
CEFUROXIME AXETIL is the injection second generation cephalosporin, is the prodrug with broad spectrum antibiotic activity cefuroxime, and its effect is stronger than the beta-lactam antibiotic of general oral absorption, and pharmacokinetic properties is good.Discharged cefuroxime and bring into play drug effect by the nonspecific esterase hydrolysis in the gastrointestinal tract mucous cell rapidly after oral.Extremely low to Toxicity of Kidney, clinical respiratory tract infection, urinary tract infection, pyelonephritis, meningitis, septicemia, the gonococcal infection etc. of being widely used in.
But, C in the cefuroxime ester structure
4Carboxyl on position degree of dissociation in vivo is big, and dissolubility is minimum in water.In addition, CEFUROXIME AXETIL bitter in the mouth, to thermally labile, easily moisture absorption, therefore, the cefuroxime ester formulation of commonsense method preparation exists disintegration time long, stripping slowly, be difficult for absorption, the quality instability, take problem such as inconvenience.
Summary of the invention
Problem to be solved by this invention is that the defective that overcomes prior art provides a kind of Cephalofruxin ester liposome, its preparation method and contains its pharmaceutical composition.
Cephalofruxin ester liposome of the present invention is made up of CEFUROXIME AXETIL, soybean lecithin and cholesterol.CEFUROXIME AXETIL: soybean lecithin: the weight ratio of cholesterol is 1:2:2.
The preparation method of Cephalofruxin ester liposome is as follows:
A. with CEFUROXIME AXETIL in CEFUROXIME AXETIL: soybean lecithin: cholesterol is that the ratio of 1:2:2 places acetone to dissolve, and recording volume filters, and evaporation is flung to acetone and become thin film, drying;
B. add phosphate buffer, soak 1-2h, high-speed stirred, after 3-20 minute, same buffer is dissolved, concentration is the 30 POVIDONE K 30 BP/USP of 0.75mg/ml to wherein slowly dripping
30Solution, and supply buffer to original volume;
C. be the 0.6-0.8um filtering with microporous membrane with the liposome turbid liquor diameter then,, get Cephalofruxin ester liposome the filtrate lyophilization that obtains.
In the preparation method of above-mentioned Cephalofruxin ester liposome, the pH value scope of used phosphate buffer is preferably 5.9-6.5, and most preferably pH value is 6.2.
Contain pharmaceutical composition, be applicable to treatment respiratory tract infection, urinary tract infection, pyelonephritis, meningitis, septicemia, gonococcal infection etc. by the Cephalofruxin ester liposome of method for preparing.
The Cephalofruxin ester liposome of the method for the invention preparation can be mixed with tablet, soft or hard capsule by suitable mode, be used to prepare the ready to use solution that adapts with its dissolubility or the particulate powder of liquid.
Preferably, the present invention makes tablet with the Cephalofruxin ester liposome of described method preparation, and this tablet is that the composition by following weight portion is prepared from: mixture 2-7 part, binding agent 2-10, the surfactant 0.5-2 of Cephalofruxin ester liposome (in cephalo skin suffering) 75-250 part, diluent 60-180 part, disintegrating agent 6-20 part, fluidizer and lubricant.
Above-mentioned diluent is selected from the mixture of microcrystalline Cellulose PH102 and lactose, and the weight ratio of preferably microcrystalline cellulose PH102 and lactose is 1.25:1.
Above-mentioned disintegrating agent is selected from one or more in dried starch, crospolyvinylpyrrolidone, cross-linking sodium carboxymethyl cellulose, the sodium carboxymethylstarch; Preferred cross-linking sodium carboxymethyl cellulose.
Above-mentioned fluidizer and lubricant mixture are selected from the mixture of micropowder silica gel and magnesium stearate; The weight ratio of preferred micropowder silica gel and magnesium stearate is 1:2.5.
Above-mentioned binding agent is selected from 30 POVIDONE K 30 BP/USP
30
Above-mentioned surfactant is selected from one or more in poloxamer 108, the sodium lauryl sulphate; Preferably sodium dodecyl sulfate.
Above-mentioned cefuroxime axetil tablet is a Film coated tablets, and wherein the film coating powder selects stomach dissolution type, and solvent selects 80% ethanol, and film coating grain weight amount and 80% ethanol volume ratio are 5:10000.
The preparation method of above-mentioned cefuroxime axetil tablet is as follows:
A. the Cephalofruxin ester liposome of the method for the invention preparation is pulverized, crossed 100 mesh sieves, standby;
B. measure various adjuvants by proportioning, cross 100 mesh sieves, press proportional quantity and above-mentioned Cephalofruxin ester liposome mix homogeneously, direct compression;
C. in film coating grain weight amount and 80% ethanol volume ratio the ratio preparation coating solution of 5:10000;
D. wrap film-coat.
Because CEFUROXIME AXETIL utmost point indissoluble in water is separated, cause that its corresponding preparation disintegration time is long, stripping is slow, the present invention makes liposome with CEFUROXIME AXETIL and preparation technology is studied, find in the research in preparation technology of the present invention when the ph of phosphate buffer value scope be between the 5.9-6.5 time, Cephalofruxin ester liposome has following characteristics: (1) Cephalofruxin ester liposome visible particles under light microscopic is even, no lumps thing; (2) the particle size distribution D of Cephalofruxin ester liposome
0.9Be 0.94; (3) the higher 75%-83% of the envelop rate of Cephalofruxin ester liposome, especially the envelop rate of liposome reaches 83% when the ph value is 6.2.To heat-labile problem, the present invention adopts freeze-drying will make the solid Cephalofruxin ester liposome, has reduced the heated time of CEFUROXIME AXETIL, has improved the stability of CEFUROXIME AXETIL at spore furan monooctyl ester raw material.
The Cephalofruxin ester liposome of the method for the invention preparation is preferably made tablet, the present invention studies cefuroxime axetil tablet and preparation technology thereof, because CEFUROXIME AXETIL utmost point indissoluble in water is separated, should consider disintegrate, the stripping of principal agent when therefore prescription designs, heated time should be avoided as far as possible or reduce to the CEFUROXIME AXETIL raw material to thermally labile in preparation process.In the research process, the present invention's prescription is selected filler: starch, lactose, microcrystalline Cellulose; Disintegrating agent: crospolyvinylpyrrolidone, cross-linking sodium carboxymethyl cellulose, carboxymethylstach sodium; Surfactant-disintegrate adjuvant: sodium lauryl sulphate, poloxamer 108: fluidizer and wetting agent: silicon dioxide, Pulvis Talci, magnesium stearate etc., in order to reduce damp and hot influence to CEFUROXIME AXETIL, the present invention adopts dry granulation, dry granulation technology is loaded down with trivial details, through test of many times, use the flowability that microcrystalline Cellulose PH102 and lactose can significantly improve material.By the orthogonal test of four factors, three levels, find with diluent be defined as mixture that microcrystalline Cellulose PH102 and magnesium stearate are 1.25:1 with the weight ratio, material fluidity was good when to be defined as micropowder silica gel and magnesium stearate be the mixture of 1:2.5 with the weight ratio with fluidizer and lubricant.
Below, compare, the superiority of effect of the present invention can be described with commercially available common cefuroxime axetil tablet by to five batch samples (lot number is respectively 060501,060502,060503,060504,060505) determination of dissolution rate.
Dissolution determination method is as follows:
Get this product, according to dissolution method (two appendix XC second methods of Chinese Pharmacopoeia version in 2005), hydrochloric acid solution 900ml with 0.07mol/l is a dissolution medium, rotating speed is that per minute 55 changes, operation in the time of 5,10,15,20,30,45 minutes, is got solution 5ml respectively in accordance with the law, filter, and in time in operator, replenish dissolution medium 5ml.It is an amount of that precision is measured subsequent filtrate respectively, be diluted to the solution that contains 15 μ g among every 1ml approximately with dissolution medium, as need testing solution (1), (2), (3), (4), (5), (6), according to ultraviolet-spectrophotography (two appendix IVA of Chinese Pharmacopoeia version in 2005), measure trap respectively at the wavelength place of 278nm; Other gets 10 of this product, porphyrize, and precision takes by weighing in right amount (it is heavy to be equivalent to average sheet), makes the solution that contains 15 μ g among every 1ml approximately by labelled amount with above-mentioned dissolution medium, in contrast product solution.Measure with method, calculate every stripping quantity at different time.
Get commercially available two kinds of common cefuroxime axetil tablets, dissolution is measured according to last method, calculates every stripping quantity at different time.
Contrast the dissolution determination result of cefuroxime axetil tablet of the present invention and commercially available common cefuroxime axetil tablet as follows:
| Time (min) | 5 10 15 20 30 45 |
| Commercially available sample (1) | 18.1 28.6 61.6 65.2 70.5 77.5 |
| Commercially available sample (2) | 21.9 30.5 65.4 67.9 73.2 76.4 |
| 060301 | 25.3 49.6 69.8 85.6 89.6 91.5 |
| 060302 | 26.8 52.1 79.4 81.9 88.3 92.8 |
| 060303 | 24.9 53.8 76.6 84.3 87.7 89.8 |
| 060304 | 31.3 48.6 75.3 82.7 89.1 93.7 |
| 060305 | 28.1 50.9 78.2 82.7 88.2 91.8 |
By the said determination result as can be known, cefuroxime axetil tablet of the present invention not only satisfies the pharmacopeia requirement, and has rapidlyer than common cefuroxime axetil tablet stripping, and drug effect is brought into play advantage faster.Owing to the principal agent of cefuroxime axetil tablet of the present invention is adopted the form of liposome, and to preparation technology's research control, realized the targeted delivery of medicine, can make medicine arrive gastrointestinal tract mucous cell quickly and accurately, thereby performance curative effect, and cefuroxime axetil tablet stable in properties of the present invention has been brought convenience to clinical application.
The specific embodiment
The invention will be further described below in conjunction with the specific embodiment.
The preparation Cephalofruxin ester liposome:
Embodiment 1:
A. recipe quantity is required CEFUROXIME AXETIL is in CEFUROXIME AXETIL: soybean lecithin: cholesterol is that the ratio of 1:2:2 places acetone to dissolve, and recording volume filters, and collects filtrate, and rotary evaporation is flung to acetone and become thin film, vacuum drying;
B. add the ph value and be 5.9 phosphate buffer, soak 1.5h, high-speed stirred after 3 minutes, is the 30 POVIDONE K 30 BP/USP of 0.75mg/ml to wherein slowly dripping the dissolved concentration of same buffer
30Solution, and supply buffer to original volume;
C. be the 0.8um filtering with microporous membrane with the liposome turbid liquor diameter then, get filtrate, filtrate is put into dish,, get Cephalofruxin ester liposome in the freeze dryer lyophilization.
Embodiment 2:
A. recipe quantity is required CEFUROXIME AXETIL is in CEFUROXIME AXETIL: soybean lecithin: cholesterol is that the ratio of 1:2:2 places acetone to dissolve, and recording volume filters, and collects filtrate, and rotary evaporation is flung to acetone and become thin film, behind the vacuum drying;
B. add the ph value and be 6.2 phosphate buffer, soak 1h, high-speed stirred after 5 minutes, is the 30 POVIDONE K 30 BP/USP of 0.75mg/ml to wherein slowly dripping the dissolved concentration of same buffer
30Solution, and supply buffer to original volume;
C. be the 0.8um filtering with microporous membrane with the liposome turbid liquor diameter then, get filtrate, filtrate is put into dish,, get Cephalofruxin ester liposome in the freeze dryer lyophilization.
Embodiment 3:
A. recipe quantity is required CEFUROXIME AXETIL is in CEFUROXIME AXETIL: soybean lecithin: cholesterol is that the ratio of 1:2:2 places acetone to dissolve, and recording volume filters, and collects filtrate, and rotary evaporation is flung to acetone and become thin film, behind the vacuum drying;
B. add the ph value and be 6.5 phosphate buffer, soak 1h, high-speed stirred after 10 minutes, is the 30 POVIDONE K 30 BP/USP of 0.75mg/ml to wherein slowly dripping the dissolved concentration of same buffer
30Solution, and supply buffer to original volume;
C. be the 0.6um filtering with microporous membrane with the liposome turbid liquor diameter then, get filtrate, filtrate is put into dish,, get Cephalofruxin ester liposome in the freeze dryer lyophilization.
Embodiment 4:
A. recipe quantity is required CEFUROXIME AXETIL is in CEFUROXIME AXETIL: soybean lecithin: cholesterol is that the ratio of 1:2:2 places acetone to dissolve, and recording volume filters, and collects filtrate, and rotary evaporation is flung to acetone and become thin film, behind the vacuum drying;
B. add the ph value and be 6.3 phosphate buffer, soak 1h, high-speed stirred after 15 minutes, is the 30 POVIDONE K 30 BP/USP of 0.75mg/ml to wherein slowly dripping the dissolved concentration of same buffer
30Solution, and supply buffer to original volume;
C. be the 0.8um filtering with microporous membrane with the liposome turbid liquor diameter then, get filtrate, filtrate is put into dish,, get Cephalofruxin ester liposome in the freeze dryer lyophilization.
Embodiment 5:
A. recipe quantity is required CEFUROXIME AXETIL is in CEFUROXIME AXETIL: soybean lecithin: cholesterol is that the ratio of 1:2:2 places acetone to dissolve, and recording volume filters, and collects filtrate, and rotary evaporation is flung to acetone and become thin film, vacuum drying;
B. add the ph value and be 6.2 phosphate buffer, soak 1h, high-speed stirred 20 minutes is the 30 POVIDONE K 30 BP/USP of 0.75mg/ml to wherein slowly dripping the dissolved concentration of same buffer
30Solution, and supply buffer to original volume;
C. be the 0.8um filtering with microporous membrane with the liposome turbid liquor diameter then, get filtrate, filtrate is put into dish,, get Cephalofruxin ester liposome in the freeze dryer lyophilization.
The preparation cefuroxime axetil tablet:
With the prepared CEFUROXIME AXETIL of any embodiment among the embodiment 1 to 5 is principal agent.
Embodiment 6: preparation specification (in cefuroxime) is 1000 of the cefuroxime axetil tablets of 75mg/ sheet, and its prescription is as follows:
Cephalofruxin ester liposome (in cephalo skin suffering) 75g
Microcrystalline Cellulose PH102 33g
Lactose 27g
Dried starch 6g
30 POVIDONE K 30 BP/USP
302g
Poloxamer 108 0.5g
Micropowder silica gel 0.57g
Magnesium stearate 1.43g
Embodiment 7: preparation specification (in cefuroxime) is 1000 of the cefuroxime axetil tablets of 125mg/ sheet, and its prescription is as follows:
Cephalofruxin ester liposome (in cephalo skin suffering) 125g
Microcrystalline Cellulose PH102 50g
Lactose 40g
Cross-linking sodium carboxymethyl cellulose 10g
30 POVIDONE K 30 BP/USP
305g
Lauryl sulphate acid 1g
Micropowder silica gel 1g
Magnesium stearate 2.5g
Embodiment 8: preparation specification (in cefuroxime) is 1000 of the cefuroxime axetil tablets of 175mg/ sheet, and its prescription is as follows:
Cephalofruxin ester liposome (in cephalo skin suffering) 175g
Microcrystalline Cellulose PH102 67g
Lactose 53g
Crospolyvinylpyrrolidone 14g
30 POVIDONE K 30 BP/USP
306g
Poloxamer 108 1.6g
Micropowder silica gel 1.14g
Magnesium stearate 2.86g
Embodiment 9: preparation specification (in cefuroxime) is 1000 of the cefuroxime axetil tablets of 225mg/ sheet, and its prescription is as follows:
Cephalofruxin ester liposome (in cephalo skin suffering) 225g
Microcrystalline Cellulose PH102 83g
Lactose 67g
Carboxymethylstach sodium 17g
30 POVIDONE K 30 BP/USP
308g
Sodium lauryl sulphate 1.8g
Micropowder silica gel 1.7g
Magnesium stearate 4.3g
Embodiment 10: preparation specification (in cefuroxime) is 1000 of the cefuroxime axetil tablets of 250mg/ sheet, and its prescription is as follows:
Cephalofruxin ester liposome (in cephalo skin suffering) 250g
Microcrystalline Cellulose PH102 100g
Lactose 80g
Cross-linking sodium carboxymethyl cellulose 20g
30 POVIDONE K 30 BP/USP
3010g
Sodium lauryl sulphate 2g
Micropowder silica gel 2g
Magnesium stearate 5g
The preparation method of the Cephalofruxin ester liposome tablet of embodiment 6 to 10 is as follows:
A. above-mentioned Cephalofruxin ester liposome is pulverized, crossed 100 mesh sieves, standby;
B. the various adjuvants of getting recipe quantity are crossed the Cephalofruxin ester liposome of 100 mesh sieves and recipe quantity, mix homogeneously, direct compression;
C. in film coating grain weight amount and 80% ethanol volume ratio the ratio preparation coating solution of 5:10000;
D. wrap film-coat.
Obviously, the above embodiment of the present invention only is for example of the present invention clearly is described, and is not to be qualification to embodiments of the present invention.For those of ordinary skill in the field, can also make other changes in different forms on the basis of the above description.Here need not also can't give exhaustive to all embodiments.And these belong to conspicuous variation or the change that spirit of the present invention extended out and still are among protection scope of the present invention.
Claims (12)
1, a kind of Cephalofruxin ester liposome is characterized in that being made up of CEFUROXIME AXETIL, soybean lecithin and cholesterol.
2, Cephalofruxin ester liposome according to claim 1 is characterized in that the weight ratio of contained CEFUROXIME AXETIL, soybean lecithin and cholesterol is: CEFUROXIME AXETIL: soybean lecithin: cholesterol=1:2:2.
3, a kind of preparation method of Cephalofruxin ester liposome is characterized in that comprising the steps:
A. place acetone to dissolve in proportion in CEFUROXIME AXETIL, soybean lecithin, cholesterol, recording volume filters, and evaporation is flung to acetone and become thin film, drying;
B. add phosphate buffer, soak 1-2h, high-speed stirred, after 3-20 minute, same buffer is dissolved, concentration is the 30 POVIDONE K 30 BP/USP of 0.75mg/ml to wherein slowly dripping
30Solution, and supply buffer to original volume;
C. be 0.8 μ m filtering with microporous membrane with above-mentioned liposome turbid liquor diameter, with the filtrate lyophilization that obtains, promptly get Cephalofruxin ester liposome again.
4, preparation method according to claim 3 is characterized in that used phosphate buffer pH value scope is 5.9-6.5.
5, preparation method according to claim 4 is characterized in that used phosphate buffer pH value is 6.2.
6, a kind of pharmaceutical composition is characterized in that contained active ingredient is the Cephalofruxin ester liposome described in the claim 1-2.
7, pharmaceutical composition according to claim 6 is characterized in that it being with the cefuroxime axetil tablet of Cephalofruxin ester liposome as active ingredient.
8, pharmaceutical composition according to claim 7, it is characterized in that described cefuroxime axetil tablet, be that each composition by following weight parts is prepared from: Cephalofruxin ester liposome is in mixture 2-7 part, binding agent 2-10 part, surfactant 0.5-2 part of cephalo skin suffering 75-250 part, diluent 60-180 part, disintegrating agent 6-20 part, fluidizer and lubricant.
9, pharmaceutical composition according to claim 8 is characterized in that described diluent is the mixture of microcrystalline Cellulose and lactose; Disintegrating agent is one or more in dried starch, crospolyvinylpyrrolidone, cross-linking sodium carboxymethyl cellulose, the sodium carboxymethylstarch; The mixture of fluidizer and lubricant is the mixture of micropowder silica gel and magnesium stearate; Binding agent is a 30 POVIDONE K 30 BP/USP
30Surfactant is one or more in poloxamer 108, the sodium lauryl sulphate.
10, pharmaceutical composition according to claim 9 is characterized in that the weight ratio of microcrystalline Cellulose PH102 and lactose is 1.25:1 in the described diluent; Disintegrating agent is a cross-linking sodium carboxymethyl cellulose; The weight ratio of micropowder silica gel and magnesium stearate is 1:2.5 in the mixture of fluidizer and lubricant; Surfactant is a sodium lauryl sulphate.
11, pharmaceutical composition according to claim 10 is characterized in that cefuroxime axetil tablet is a Film coated tablets, and the film coating powder is a stomach dissolution type, and solvent is 80% ethanol, and the weight of film coating powder and solvent 80% alcoholic acid volume ratio are 5:10000.
12, a kind of Cephalofruxin ester liposome preparation of drug combination method is characterized in that comprising the steps:
A. Cephalofruxin ester liposome is pulverized, crossed 100 mesh sieves, standby;
B. measure various adjuvants by proportioning, cross 100 mesh sieves; Press proportional quantity and above-mentioned Cephalofruxin ester liposome mix homogeneously, direct compression;
C. in proportion with film coating powder and 80% ethanol preparation coating solution;
D. wrap film-coat.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006101497036A CN100490807C (en) | 2006-10-23 | 2006-10-23 | Cephalofruxin ester liposome, its preparation and medicinal composition containing it |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006101497036A CN100490807C (en) | 2006-10-23 | 2006-10-23 | Cephalofruxin ester liposome, its preparation and medicinal composition containing it |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1939305A CN1939305A (en) | 2007-04-04 |
| CN100490807C true CN100490807C (en) | 2009-05-27 |
Family
ID=37958011
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2006101497036A Active CN100490807C (en) | 2006-10-23 | 2006-10-23 | Cephalofruxin ester liposome, its preparation and medicinal composition containing it |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100490807C (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101810610A (en) * | 2010-04-19 | 2010-08-25 | 海南美兰史克制药有限公司 | Amoxicillin sodium flucloxacillin sodium medicine compound liposome injection |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101444514B (en) * | 2008-12-29 | 2011-07-06 | 海南灵康制药有限公司 | Cefmenoxime hydrochloride preparation for injection and preparation method thereof |
| CN101912363A (en) * | 2010-07-29 | 2010-12-15 | 蔡海德 | Dissolving ultrafiltration-spray drying-molecule dispersion coating-hydration palletizing-freeze drying method for preparing liposome combination medicine |
| CN101966161B (en) * | 2010-09-06 | 2012-05-23 | 海南美兰史克制药有限公司 | Rabeprazole sodium liposome enteric-coated tablets |
| CN102091044B (en) * | 2011-01-27 | 2012-05-23 | 海南美大制药有限公司 | Cefuroxime axetil lipid microsphere solid preparation |
| CN103027899B (en) * | 2012-12-31 | 2014-12-17 | 苏州中化药品工业有限公司 | Cephalosporin ester drug particle in non-gel state after meeting water, and preparation method and application of drug particle |
| CN103006614B (en) * | 2012-12-31 | 2014-10-08 | 苏州中化药品工业有限公司 | Cefuroxime axetil capsule in non-gel state in water and preparation method of cefuroxime axetil capsule |
| CN105640954B (en) * | 2016-02-04 | 2019-03-05 | 青岛市海慈医疗集团 | It is a kind of to treat dyspeptic Cisapride tablet |
| CN107569466A (en) * | 2017-09-17 | 2018-01-12 | 石家庄四药有限公司 | Cefuroxime axetil pharmaceutical composition prepared by a kind of direct compression method |
-
2006
- 2006-10-23 CN CNB2006101497036A patent/CN100490807C/en active Active
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101810610A (en) * | 2010-04-19 | 2010-08-25 | 海南美兰史克制药有限公司 | Amoxicillin sodium flucloxacillin sodium medicine compound liposome injection |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1939305A (en) | 2007-04-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100490807C (en) | Cephalofruxin ester liposome, its preparation and medicinal composition containing it | |
| JP2021178871A (en) | Formulations of enzalutamide | |
| US7732492B2 (en) | Nateglinide-containing preparation | |
| EP1886673B1 (en) | Solid dosage form of enteric solid dispersion and method for producing the same | |
| JP2018184410A (en) | Pharmaceutical composition containing amorphous dapagliflozin | |
| CN101450212A (en) | Solid pharmaceutical dispersions with enhanced bioavailability | |
| CN106102716A (en) | The solid composite medicament of androgen receptor antagonists | |
| MX2009002336A (en) | Imatinib compositions. | |
| Augsburger et al. | Super disintegrants: characterization and function | |
| CN105722513A (en) | Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis | |
| CN104940158A (en) | Medicine composition containing cefuroxime axetil and preparation method of medicine composition | |
| CN105456270A (en) | Dipeptidyl peptidase IV inhibitor pharmaceutical composition, use and preparation method thereof | |
| US20090209587A1 (en) | Repaglinide formulations | |
| EP2934488B1 (en) | A pharmaceutical composition containing candesartan cilexetil and amlodipine | |
| CN102406622A (en) | Tolvaptan solid preparation | |
| Sun et al. | A microcrystalline cellulose based drug-composite formulation strategy for developing low dose drug tablets | |
| EP2692340B1 (en) | Stable pharmaceutical system (kit) for the preparation of oral solution of levothyroxine or pharmaceutically acceptable salt thereof | |
| CN104510707A (en) | Posaconazole solid dispersion and preparation method thereof | |
| CN103919744B (en) | A kind of Cefteram Pivoxil Tablets and preparation technology thereof | |
| US20040022855A1 (en) | Cored tablets comprising amoxicillin and clavulanate | |
| CN107530342A (en) | Oral administration medical composition | |
| CN104721827A (en) | Insoluble antifungal medicament solid dispersion and preparation method thereof | |
| CN105435239A (en) | Use of microcrystalline cellulose in Meisuoshuli preparation, auxiliary material used for Meisuoshuli, Meisuoshuli preparation and preparation method of Meisuoshuli preparation | |
| CN108186590A (en) | Huperzine slow-release orally disintegrating tablets and preparation method thereof | |
| CN110314150A (en) | A kind of Telmisartan flavor chewable tablets and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Assignee: CSPC Hebei Zhongrun Pharmaceutical Co., Ltd. Assignor: Shijiazhuang Pharmaceutical Group Ouyi Pharma Co., Ltd. Contract record no.: 2011130000082 Denomination of invention: Cephalofruxin ester liposome, its preparation and medicinal composition containing it Granted publication date: 20090527 License type: Exclusive License Open date: 20070404 Record date: 20110627 |
|
| EM01 | Change of recordation of patent licensing contract |
Change date: 20120525 Contract record no.: 2011130000082 Assignee after: Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd., Shiyao Group Assignee before: CSPC Hebei Zhongrun Pharmaceutical Co., Ltd. |